Efficacy Study for Treatment of Dementia in Progressive Supranuclear Palsy
- Registration Number
- NCT00522015
- Lead Sponsor
- University Hospital Tuebingen
- Brief Summary
to show that
1. patients improve and stabilize after 12 -24 week treatment with rivastigmine in memory function
2. use of rivastigmine has a positive effect on apathy in PSP patients
3. therapy with rivastigmine has a no positive benefit on speech and overall results of the MMST
4. changes in motor activity are associated with changes in language and overall results of the in MMST
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
- diagnosis of PSP
- willingness to participate in the study
- informed consent
- ability to speak
- no further CNS diseases
- written informed consent
- stable state of health
- ability to give informed consent, will checked by an independent physician
Exclusion Criteria
- alcohol abuses
- acute psychosis
- pregnancy or lactation
- known previous drug reaction or hypersensitivity of rivastigmine or other carbamate derivatives
- liver failure
- known sick sinus syndrome or excitation disturbance
- known ulcus ventriculi or duodenal ulcer
- known asthma or COPD
- seizures
- renal failure
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description 1 rivastigmine patients take 6 mg rivastigmine daily, if well tolerable increase to 12 mg rivastigmine maximum daily
- Primary Outcome Measures
Name Time Method improvement in neuropsychological assessments for memory and executive function, e.g. tested by "Tower of London Test, CERAD Battery and Logical Memory Test (WMSR)" 6 month
- Secondary Outcome Measures
Name Time Method changes in speech function and improvement of quality of life 6 Month
Trial Locations
- Locations (1)
University of Tuebingen
🇩🇪Tuebingen, Baden Wuerttemberg, Germany